Results 151 to 160 of about 7,093,593 (187)

Bone Marrow Mononuclear Cells and Plasma Gel as Combination Treatment for Hard-to-Heal Wounds. [PDF]

Life (Basel)
Perez-Lopez S, Vazquez-Garcia N, Rodriguez-Martinez ML, Valerdiz-Casasola S, Perez-Basterrechea M, Garcia-Gala JM, Fernandez-Rodriguez MLA, Martinez-Revuelta E, Alvarez-Viejo M.   +8 more
europepmc   +1 more source

Do conditional marketing authorisations actually accelerate patient access? Time-to-access of conditional vs. standard marketing authorisations in Italy, Spain, and Germany. [PDF]

J Pharm Policy Pract
Ardito V, Falk L, Gasol Boncompte M, Pontes C, Robinson J, Schreyögg J, Ciani O.   +6 more
europepmc   +1 more source

Editorial: Methods in alloimmunity and transplantation: 2025. [PDF]

Front Immunol
Kauke-Navarro M, Moll G.
europepmc   +1 more source

A decade of innovation in healthcare: Automation, bio-printing and digital twin technologies for personalized therapies. [PDF]

Int J Pharm X
Ghavami D, Giulietti N, Sandri G, Giberti H.   +3 more
europepmc   +1 more source

Addressing clinical uncertainties in ATMP reimbursement: a review of methodological guidelines and European practice. [PDF]

Front Pharmacol
Delemarre L, Huys I, Van Dyck W, Simoens S.   +3 more
europepmc   +1 more source

Eigenfetttransplantationen als Anwendungsfall von Advanced Therapy Medicinal Products i.S.d. ATMP-VO

openaire   +1 more source

Unlocking the value of innovative medicines: Insights from the advanced therapy medicinal products (ATMP) innovation systems in Germany and Sweden

Health Policy and Technology, 2023
Objectives: Generally low uptake in the advanced therapy medicinal products (ATMP) market and difficult patient access has been observed across Europe.
Heike Aichinger, Jörg Mahlich, Tanja Bratan   +2 more
exaly   +2 more sources

Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective [PDF]

Frontiers in Medicine, 2022
Advanced Therapy Medicinal Products (ATMPs) comprising cell, gene, and tissue-engineered therapies have demonstrated enormous therapeutic benefits. However, their development is complex to be managed efficiently within currently existing regulatory ...
Enrico Fritsche, Petra Reinke, Leila Amini   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Payer and Implementation Challenges with Advanced Therapy Medicinal Products (ATMPs)

BioDrugs, 2020
Advanced therapy medicinal products (ATMPs) are a dynamic and current topic for healthcare systems, with new products progressing to market at an increasing rate. ATMPs highlight the growing gap between payer and regulator requirements; the limited evidence base combined with pressure to implement rapidly is exacerbating the clinical and financial ...
John Spoors, Alec Miners, John Cairns, Danny Palnoch, Ash Summerfield, Joanne McEntee, Sheena Vithlani   +6 more
openaire   +2 more sources

Advanced Therapy Medicinal Products (ATMPs)

2022
Over the last few decades a new group of medicinal products have emerged and have been named advanced therapy medicinal products (ATMPs). These are categorised separately from conventional treatments such as pharmaceuticals and medical devices due to their biological origin.
M. L. D. Rayner, J. B. Phillips
openaire   +1 more source